Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease
- PMID: 20678071
- DOI: 10.2174/156720510793611556
Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease
Abstract
Deposits of the misfolded neuronal protein tau are major hallmarks of neurodegeneration in Alzheimer's disease (AD) and other tauopathies. The etiology of the transformation process of the intrinsically disordered soluble protein tau into the insoluble misordered aggregate has attracted much attention. Tau undergoes multiple modifications in AD, most notably hyperphosphorylation and truncation. Hyperphosphorylation is widely regarded as the hottest candidate for the inducer of the neurofibrillary pathology. However, the true nature of the impetus that initiates the whole process in the human brains remains unknown. In AD, several site-specific tau cleavages were identified and became connected to the progression of the disease. In addition, western blot analyses of tau species in AD brains reveal multitudes of various truncated forms. In this review we summarize evidence showing that tau truncation alone is sufficient to induce the complete cascade of neurofibrillary pathology, including hyperphosphorylation and accumulation of misfolded insoluble forms of tau. Therefore, proteolytical abnormalities in the stressed neurons and production of aberrant tau cleavage products deserve closer attention and should be considered as early therapeutic targets for Alzheimer's disease.
Similar articles
-
Tau mediated neurodegeneration: an insight into Alzheimer's disease pathology.Neurochem Res. 2011 Aug;36(8):1329-35. doi: 10.1007/s11064-011-0475-5. Epub 2011 Apr 21. Neurochem Res. 2011. PMID: 21509508 Review.
-
A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.J Alzheimers Dis. 2010;21(2):445-70. doi: 10.3233/JAD-2010-100120. J Alzheimers Dis. 2010. PMID: 20571215
-
Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.J Neurogenet. 2011 Dec;25(4):127-33. doi: 10.3109/01677063.2011.626471. J Neurogenet. 2011. PMID: 22091726 Review.
-
Transition of tau protein from disordered to misordered in Alzheimer's disease.Neurodegener Dis. 2010;7(1-3):24-7. doi: 10.1159/000283478. Epub 2010 Feb 13. Neurodegener Dis. 2010. PMID: 20160453
-
Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.Curr Opin Psychiatry. 2008 Nov;21(6):555-61. doi: 10.1097/YCO.0b013e328314b78b. Curr Opin Psychiatry. 2008. PMID: 18852562 Review.
Cited by
-
Secondary nucleating sequences affect kinetics and thermodynamics of tau aggregation.Biochemistry. 2011 Dec 20;50(50):10876-86. doi: 10.1021/bi2014745. Epub 2011 Nov 29. Biochemistry. 2011. PMID: 22085312 Free PMC article.
-
Fairy "tails": flexibility and function of intrinsically disordered extensions in the photosynthetic world.Front Mol Biosci. 2015 May 19;2:23. doi: 10.3389/fmolb.2015.00023. eCollection 2015. Front Mol Biosci. 2015. PMID: 26042223 Free PMC article. Review.
-
The Distance between N and C Termini of Tau and of FTDP-17 Mutants Is Modulated by Microtubule Interactions in Living Cells.Front Mol Neurosci. 2017 Jun 30;10:210. doi: 10.3389/fnmol.2017.00210. eCollection 2017. Front Mol Neurosci. 2017. PMID: 28713242 Free PMC article.
-
Intersection of pathological tau and microglia at the synapse.Acta Neuropathol Commun. 2019 Jul 5;7(1):109. doi: 10.1186/s40478-019-0754-y. Acta Neuropathol Commun. 2019. PMID: 31277708 Free PMC article. Review.
-
Signaling pathways and posttranslational modifications of tau in Alzheimer's disease: the humanization of yeast cells.Microb Cell. 2016 Mar 25;3(4):135-146. doi: 10.15698/mic2016.04.489. Microb Cell. 2016. PMID: 28357346 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical